Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: A randomized, controlled, phase II trial in Latin America

Pediatric Infectious Disease Journal

Volumn 32, Issue 10, 2013, Pages 1102-1109

  Villar, Luis Á ^a   Rivera Medina, Doris M ^b   Arredondo García, José Luis ^c   Boaz, Mark ^d   Starr Spires, Linda ^d   Thakur, Manoj ^d   Zambrano, Betzana ^e   Miranda, María C ^f   Rivas, Enrique ^g   Dayan, Gustavo H ^d  

^a UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^b Organización Para El Desarrollo y la Investigación Salud en Honduras   (Honduras)

^c INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^d SANOFI PASTEUR   (France)

^e Sanofi Pasteur   (Uruguay)

^f Sanofi Pasteur   (Colombia)

^g Sanofi Pasteur   (Mexico)

Author keywords

Clinical trial; Dengue disease; Latin America; Pediatric population; Vaccine

Indexed keywords

DENGUE VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; LIVE VACCINE; PLACEBO; RECOMBINANT VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHENIA; CHILD; COLOMBIA; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HONDURAS; HUMAN; HUMAN EXPERIMENT; IMMUNE STATUS; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MEXICO; MYALGIA; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUERTO RICO; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SERODIAGNOSIS; SEROTYPE; URINARY TRACT INFECTION; VIRUS PLAQUE; VIRUS STRAIN;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; DENGUE; DENGUE VACCINES; FEMALE; HUMANS; LATIN AMERICA; MALE; SINGLE-BLIND METHOD; VACCINES, SYNTHETIC;

EID: 84885432447     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829b8022     Document Type: Article

References (27)

1. Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Howley PM. Fields Virology. 4th ed. Vol Philadelphia, PA : Lippincott Williams & Wilkins; 2001: 1043-1125.
2. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. New edition. Geneva. 2009. Available at: http://whqlibdoc.who.int/publications/2009/9789241547871-eng.pdf. Accessed August 1, 2012.
3. San Martín JL, Brathwaite O, Zambrano B, et al. The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am J Trop Med Hyg. 2010;82: 128-135.
4. Hurtado-Díaz M, Riojas-Rodríguez H, Rothenberg SJ, et al. Short communication: impact of climate variability on the incidence of dengue in Mexico. Trop Med Int Health. 2007;12: 1327-1337.
5. Barclay E. Is climate change affecting dengue in the Americas? Lancet. 2008;371: 973-974.
6. Pan American Health Organization. Dengue. 2012. Available at: http://new. paho.org/hq/index.php?option=com-content&task=view&id=264&Itemid =363&lang=es. Accessed August 1, 2012.
7. Guirakhoo F, Weltzin R, Chambers TJ, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000;74: 5477-5485.
8. Guirakhoo F, Arroyo J, Pugachev KV, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001;75: 7290-7304.
9. Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28: 632-649.
10. Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29: 7229-7241.
11. Qiao M, Shaw D, Forrat R, et al. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg. 2011;85: 724-731.
12. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006;2: 60-67.
13. Morrison D, Legg TJ, Billings CW, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010;201: 370-377.
14. Capeding RZ, Luna IA, Bomasang E, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011;29: 3863-3872.
15. Poo J, Galan F, Forrat R, et al. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. 2011;30:e9-e17.
16. Lanata CF, Andrade T, Gil AI, et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine. 2012;30: 5935-5941.
17. Sin Leo Y, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012;8: 1259-1271.
18. Mantel N, Aguirre M, Gulia S, et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods. 2008;151: 40-46.
19. Russell PK, Nisalak A, Sukhavachana P, et al. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol. 1967;99: 285-290.
20. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008;21: 123-132.
21. Huhtamo E, Hasu E, Uzcátegui NY, et al. Early diagnosis of dengue in travelers: comparison of a novel real-time RT-PCR, NS1 antigen detection and serology. J Clin Virol. 2010;47: 49-53.
22. Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26: 404-413.
23. Campbell GL, Grady LJ, Huang C, et al. Laboratory testing for West Nile virus: panel discussion. Ann N Y Acad Sci. 2001;951: 179-194.
24. Houghton-Triviño N, Montaña D, Castellanos J. Dengue-yellow fever sera cross-reactivity; challenges for diagnosis. Rev Salud Publica (Bogota). 2008;10: 299-307.
25. Mansfield KL, Horton DL, Johnson N, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92(Pt 12): 2821-2829.
26. Pan American Health Organization. Epidemiological alert: regional update on dengue. Dengue outbreaks in the Americas. 8 March 2010. Available at: http://new.paho.org/hq/dmdocuments/2010/epi-alerts-2010-08-March- dengue-outbreaks.pdf. Accessed August 1, 2012.
27. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai school children: a randomised, controlled phase IIb trial. Lancet. 2012;380: 1559-1567.